Background: Azathioprine (AZA) and mercaptopurine (MP) are the cornerstone of
| INTRODUCTION
Autoimmune hepatitis (AIH) is an immune-mediated inflammation of unknown aetiology primarily targeting hepatocytes, usually requiring lifelong immunosuppressive therapy. Treatment is aimed to prevent disease relapse, relief symptoms and achieve complete biochemical and histological normalisation in order to prevent progression to fibrosis, cirrhosis and end-stage liver failure requiring liver transplantation. 1 Remission is induced using prednisone and often maintained by a corticosteroid-saving regime using thiopurines: azathioprine (AZA) or mercaptopurine (MP). 2 Unfortunately, up to 20% of patients do not respond to or tolerate these conventional thiopurines. 3 Currently, rescue medications are limited to mycophenolate mofetil, tacrolimus and ciclosporin. The European AIH guideline commemorate states that patients intolerant to AZA can be offered tioguanine (TG) therapy as alternative to mycophenolate mofetil, although there is only anecdotic evidence available to support its use. 1 Tioguanine, a rediscovered thiopurine for inflammatory bowel disease can be interchanged with AZA and MP. 4, 5 Based on a single study addressing potential side effects related to TG use, there has been initial concern about the safety of this drug, 6 yet well-designed additional studies in different cohorts of inflammatory bowel disease patients have not found evidence to support this assumption. 7 Azathioprine and MP are metabolized by a shared pathway via thiopurine S-methyltransferase, into hepatotoxic breakdown metabolites 6-methyl MP and by other enzymatic steps into the pharmacologically active compound 6-tioguaninenucleotide (6-TGN). TG is metabolized directly to 6-TGN and to 6-methyltioguanine, the latter also by thiopurine S-methyltransferase. Deficient forms of thiopurine S-methyltransferase leads to toxic levels of 6-TGN when a patient is on TG therapy, causing bone marrow suppression. However, the absolute burden of methylated side products is much lower during use of TG when compared to the larger thiopurines AZA and MP.
Hence, TG therapy might be as effective as other thiopurines, but be better tolerated in the treatment of AIH.
In 2005, our group published the first data on TG therapy in three AIH patients, 8 and more recently another group performed a single -centre study in a small and heterogeneous group of patients with AIH and AIH variant syndrome. 9 To extend the experience with International AIH Group scores were calculated. 10 All were initiated haemoglobin <7.5 mmol/L, male: haemoglobin <8.5 mmol/L). One hepatopathologist assessed the majority of follow-up biopsies; nodular regenerative hyperplasia was defined according to the consensus criteria on the existing histopathologic diagnosis of nodular regenerative hyperplasia by Jharap et al. 14 Abdominal imaging reports and gastroscopy reports were assessed for signs of portal hypertension.
| Efficacy
Complete biochemical remission was defined as serum alanine aminotransferase (ALT), serum aspartate aminotransferase and, when available, serum immunoglobulin G (IgG) within the normal range. Incomplete response was defined as an ALT of >1 and <2 times the upper limit of normal and nonresponse as an ALT of >2 times the upper limit of normal. 1 Biochemical relapse was defined as an increase of ALT >3 times the upper limit of normal or an increase of IgG to >20 g/L. 
| RESULTS
A total of 52 patients including AIH (n = 39) and AIH variant syndrome (n = 10) patients who were treated with TG as rescue treatment after failing on AZA or MP as well as three thiopurine-naïve AIH patients who were treated with TG as first-line therapy were included in this study. Characteristics and treatment details are summarised in Table 1 .
| Adverse events
Tioguanine therapy (20 mg/day, range: 10-24 mg/day) was well-tolerated in 41 (79%) patients, whereas four experienced tolerable (8%) and seven (13%) experienced intolerable side effects. A description of the adverse events reported on previous AZA and MP (44 of 49 patients; 90%) and those reported on subsequent TG therapy is provided in Table 2 . Complaints of arthralgia recurred in one patient after switching to TG therapy, whereas all other patient-reported side effects on TG therapy differed from those reported on the origi- were recorded in patients while they were treated with TG.
| TG Efficacy in AIH patients
Thirty-three AIH patients were treated with TG after intolerable side effects on AZA or MP (Table 2) . At the time of last follow-up, TG Early biochemical response to TG therapy was measured at 1 and 3 months. At baseline 9 of 39 (23%) patients had complete biochemical remission; this increased to 19 of 38 (50%, P = 0.002), and 19 of 34 (56%, P < 0.001) after 1 and 3 months, respectively (Table 3 ).
Serum ALT levels are shown in Figure 1 . The median IgG levels were similar at 1, 3 and 12 months compared with baseline ( Figure 2 ).
Prednisolone or budesonide was used by 32 (87%) patients at the time of initiation of TG therapy. A decrease in glucocorticoid dose of >25% was achieved in 18 (56%) patients at the last followup. Complete withdrawal of steroids was achieved in six of these patients. Two (6%) patients required a steroid dose escalation. Steroids were initiated in another two (6%) patients.
Two AIH patients who were in remission for 1 year, temporarily discontinued TG, one patient in a drug withdrawal attempt as agreed with the treating physician and another patient refused to switch between two brands of TG. Both relapsed after 3 and 18 months respectively. After remission was induced with prednisone, complete biochemical remission was again maintained with TG monotherapy (20 mg/day) in both patients with a follow-up of 6 months.
| AIH variant syndromes
Treatment details of 10 patients with AIH variant syndromes who failed on conventional treatment are depicted in Table 4 Table 4 ).
The median alkaline phosphatase at diagnosis of AIH variant patients was 258 U/L (range 74-757). Alkaline phosphatase levels during TG therapy are shown in Figure S1 .
| First-line maintenance therapy
In three patients with established AIH 10 (post-treatment International AIH Group scores of 13-16), TG was initiated as the first steroid sparing agent, based on the judgement of the treating physician. TG therapy was initiated after diagnosis in two and after a flare while on monotherapy budesonide in another.
Two patients achieved complete biochemical remission after 6 months of TG therapy, which led to complete withdrawal of budesonide in one patient and tapering of prednisolone from 30 to 10 mg/day in the other. The third patient was followed for 1 month, in which she tolerated TG treatment.
| Cirrhosis in AIH and AIH variant patients
Cirrhosis was present in eight (16%) and fibrosis in 22 (45%) of 49 patients who were biopsied prior to TG therapy. Two patients were not biopsied at diagnosis, due to coagulopathy and the histology report of another patient could not be retrieved. Twenty-eight biopsies were performed in 10 patients on TG therapy, after a median treatment of 56 months (range 10-111). Progression from fibrosis to cirrhosis occurred in one of the 10 biopsied patients. Of relevance, there were no cases of nodular regenerative hyperplasia identified in histology.
| Drug adherence in AIH and AIH variant patients
In 30 patients, a total of 51 serum 6-TGN levels were measured at least 4 weeks after first TG administration. Our data show that the vast majority of patients with AIH and AIH variants with prior intolerable side effects on conventional thiopurines will tolerate TG therapy. Similarly, nearly all patientreported tolerable side effects disappeared after switching to TG therapy. The side effects reported on TG therapy differed from those reported on the original thiopurine and switching resulted in normalisation of full blood count outcomes in all but one patient with myelosuppression in our cohort, which is supported by recent data in the field of inflammatory bowel disease. 4, 19 The favourable tolerability might be explained by the one-step metabolism of TG into the pharmacologically effective 6-TGNs, without the formation of potentially toxic 6-methyl MP metabolites seen in the complex metabolism of AZA and MP. Although this metabolism can effectively be skewed towards 6-TGN formation by adding low-dose allopurinol or mesalazine, 20 direct TG therapy would prevent addition of another drug.
In our cohort, TG was effective in the majority (85%) of AIH patients with prior intolerance on conventional thiopurines. This is in line with a recent small single centre study, where 17 AIH patients who had failed on AZA were switched to TG. 9 Although switching patients from one thiopurine to another after incomplete response was ineffective in prior studies, 9,21 two AIH and two AIH-PSC patients in our cohort achieved complete biochemical remission with TG therapy after insufficient response on other thiopurines.
Patients with AIH who fail AZA have limited rescue options with the most frequently used second line treatment being mycophenolate mofetil. The success rate of TG therapy in our cohort was slightly higher compared to mycophenolate mofetil for those patients who switched due to intolerable side effects (85% vs 43%-75%) or due to insufficient response on conventional thiopurines (50% vs | 765 20%-34%). [22] [23] [24] A multicentre study with a considerable experience in AIH patients (n = 105) treated with mycophenolate mofetil reported 25% tolerable and 9% intolerable side effects, which is comparable to our data in patients using TG. 24 Serious adverse events occurred in three patients using mycophenolate mofetil, which we did not observe in our cohort.
Metabolite measurements show that all but one of the patients tested were adherent to TG therapy, confirming that this is a useful tool for adherence monitoring, but due to infrequent 6-TGN measurements, insufficient data was available for dose-response and toxicity profiles analyses.
Concerns regarding nodular regenerative hyperplasia were not substantiated in this cohort, in which despite available histological follow-up no cases were identified. This can be explained by the relatively low dose compared with the original oncological and inflammatory bowel disease studies in which nodular regenerative hyperplasia was identified. Moreover, a review in patients with inflammatory bowel disease showed that considerably less nodular regenerative hyperplasia occurred when dosages of TG did not exceed 25 mg/day. 7 In addition, no association was found between nodular regenerative hyperplasia and clinically significant liver disease, in a recent inflammatory bowel disease study. 25 There were no cases of pancreatitis in our cohort.
This study encompasses experience on a national-level leading to generalisable results of AIH patients who received TG therapy. Other strengths of this study are the large number of patients in a real-life cohort, the strict complete biochemical remission and the separate analysis of variant syndromes. It should be noted that this study was not powered for safety analysis and despite measures to control for ascertainment bias, adverse events may have been missed. Due to the retrospective nature of this study, it was not possible to control for co-medication which might have biased the response rate. However, corticosteroid dose could be decreased in most patients, while maintaining remission.
In conclusion, our data show that TG therapy with a median dose of 20 mg/day is tolerated and leads to complete biochemical remission in selected patients with AIH or AIH variants who were previously intolerant and in some patients with prior insufficient response on conventional thiopurines. 
